Clinical observation of lenalidomide in treatment of high-intermediate-risk B-cell non-Hodgkin lymphoma
10.3760/cma.j.issn.1009-9921.2019.02.008
- VernacularTitle:来那度胺治疗中高危B细胞非霍奇金淋巴瘤临床观察
- Author:
Lei HUANG
1
;
Qing YU
;
Chao WU
;
Wenbin XU
;
Chenjing YE
;
Hua YAN
Author Information
1. 上海交通大学医学院附属瑞金医院特需医疗中心 200025
- Keywords:
Lymphoma,non-Hodgkin;
Lenalidomide;
High-intermediate-risk;
Treatment
- From:
Journal of Leukemia & Lymphoma
2019;28(2):91-95
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of the lenalidomide-based therapy regimen in the treatment of high-intermediate-risk B-cell non-Hodgkin lymphoma (B-NHL). Methods A retrospective analysis of 23 high-intermediate-risk B-NHL patients who were admitted to Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine from June 2015 to February 2018 was conducted, of which 7 relapsed or refractory (R/R) patients received lenalidomide combined with rituximab (R2) and plus different salvage chemotherapy regimens (DHAP, GDP, ICE) of each 28-day cycle; 5 elderly patients were initially treated with R2 of each 28-day cycle; 11 patients were administered by maintenance monotherapy of lenalidomide of each 28-day cycle, or R2 therapy of 3-month cycle. The primary endpoint was overall response, and the secondary endpoints were progression-free survival (PFS) and safety. Results The median follow-up time was 4.5 months (1-20 months) in the R/R and elderly initial-treated patients. The median time to response in the R/R group was 3 months (2-7 months), of which 3 patients were complete remission (CR), overall response was 3 patients, and the median PFS was 7 months. The median time to response in the elderly initial treatment group was 4 months (2-5 months), 1 of 4 eligible patients was CR and 2 were partial remission (PR), overall response was 3 patients, and the median PFS time had not reached. The median follow-up time in the maintenance treatment group was 15 months (2-32 months), the median PFS time had not reached, and the 1-year PFS rate was 64％ (95％ CI 36％-92％). The most common grade 3-4 adverse events were leukopenia and thrombocytopenia, each accounting for 35％, and most patients were tolerable. Conclusion Lenalidomide as an immunomodulator is effective and safety for elderly initial treatment, R/R and maintenance treatment patients with high-intermediate-risk B-NHL, and it can prolong their survival.
